Yu Yanlong, Song Jiuling, Zhang Ran, Liu Zhonghua, Li Qiang, Shi Ying, Chen Ying, Chen Jinming
Department of General Surgery, Chifeng Municipal Hospital, Inner Mongolia Medical University institute of clinical, Chifeng 024000, Inner Mongolia Autonomous Region, China.
Oncotarget. 2017 Jul 12;8(45):79722-79730. doi: 10.18632/oncotarget.19178. eCollection 2017 Oct 3.
Small hepatocellular carcinoma (HCC) is less invasive and has a better prognosis, but it still has a high recurrence rate. Microvascular invasion (MVI), as a poor prognostic indicator, is of great importance for treating of patients with HCC. The objective of the present study was to evaluate the predictive value of preoperative neutrophil-to-lymphocyte ratio and possible clinical parameters to MVI in patients with HCC. A total of 157 operable patients with HCC having a tumor diameter of less than or equal to 5 cm were enrolled in this study. The utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and other clinical parameters was evaluated using receiver operating characteristic curves. MVI was identified as an independent influencing factor for disease-free survival in patients with HCC who underwent curative resection, using the multivariate Cox proportional hazards regression model. The independent parameters associated with MVI were determined using logistic analysis. Multivariate analyses indicated that the neutrophil-to-lymphocyte ratio [hazard ratio, 1.705; 95% confidence interval, 0.467-6.232; = 0.022)], platelet-to-lymphocyte ratio (hazard ratio, 1.048; 95% confidence interval, 1.006-1.092; = 0.025), and a-fetoprotein (hazard ratio, 1.012; 95% confidence interval, 1.003-1.021; = 0.007) were significantly associated with MVI independently. Therefore, this study concluded that the preoperative neutrophil-to-lymphocyte ratio and a-fetoprotein might serve as useful biomarkers for predicting MVI in patients with HCC.
小肝细胞癌(HCC)侵袭性较低,预后较好,但复发率仍较高。微血管侵犯(MVI)作为一种预后不良指标,对于HCC患者的治疗具有重要意义。本研究的目的是评估术前中性粒细胞与淋巴细胞比值及其他可能的临床参数对HCC患者MVI的预测价值。本研究共纳入157例肿瘤直径小于或等于5 cm的可手术HCC患者。使用受试者工作特征曲线评估中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及其他临床参数的效用。采用多因素Cox比例风险回归模型,将MVI确定为接受根治性切除的HCC患者无病生存的独立影响因素。使用逻辑分析确定与MVI相关的独立参数。多因素分析表明,中性粒细胞与淋巴细胞比值[风险比,1.705;95%置信区间,0.467 - 6.232;P = 0.022]、血小板与淋巴细胞比值(风险比,1.048;95%置信区间,1.006 - 1.092;P = 0.025)和甲胎蛋白(风险比,1.012;95%置信区间,1.003 - 1.021;P = 0.007)均独立与MVI显著相关。因此,本研究得出结论,术前中性粒细胞与淋巴细胞比值和甲胎蛋白可能作为预测HCC患者MVI的有用生物标志物。